MISSISSAUGA, ON, Nov. 10, 2014 /CNW/ - Covalon Technologies Ltd, (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be promoting its world class products and technologies at both MEDICA and at WOUNDS UK this week.
"We are very excited to be back at MEDICA in 2014 with our patented line of professional skin care, advanced interactive wound care, and infection control products, some of which, will be showcased for the first time in Dusseldorf," said John R. Hands, Senior Director of Marketing at Covalon. "Medica is a great opportunity to introduce new, innovative products, connect with existing customers and hundreds of medical companies that can become new partners for Covalon."
ColActive Transfer, the world's only interactive wound contact layer will be the centerpiece of this year's Advanced Wound Care line-up. "Protecting fragile granulation tissue while simultaneously providing bio-activity to stimulate wound closure is an enviable competitive advantage, especially with the growing popularity of treatments like Negative Pressure Wound Therapy" Hands continued.
Covalon's Chief Scientific Officer, Dr. Val. DiTizio will be presenting multiple scientific posters at WOUNDS UK, demonstrating the superiority of the Company's dual antimicrobial clear silicone adhesive technology. In November, 2013, Covalon announced that it had granted Molnlycke Health Care the exclusive rights to exploit Covalon's patent-pending antimicrobial silicone adhesive technology in the field of single-use surgical, wound care and vascular access medical dressings. Dr. DiTizio will be presenting the scientific posters in support of Molnlycke Healthcare's marketing efforts of Covalon's technology.
MEDICA, the world's largest medical technology trade fair in Düsseldorf, Germany, runs from November 12-15th and hosts 4,500 exhibitors from 70 countries. Covalon's booth is located in Hall 16, Stand G42.
The Wounds UK Annual Conference will be held on November 10-12th at the Harrogate International Centre in Harrogate, UK and is the largest wound care conference in the United Kingdom, attracting over 1,700 delegates.
"Covalon is looking forward to assisting Molnlycke with their international promotional efforts of the technology licensed from Covalon," said Hands. "We are encouraged with the opportunity to speak about our technology with an ever expanding group of wound care professionals."
For more information about the MEDICA, please visit http://www.medica-tradefair.com/
For more information about the WOUNDS UK, please visit http://www.wounds-uk.com/.
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
Image with caption: "Covalon Technologies Ltd. (CNW Group/Covalon Technologies Ltd.)". Image available at: http://photos.newswire.ca/images/download/20141110_C5845_PHOTO_EN_7776.jpg
SOURCE: Covalon Technologies Ltd.
For further information: To learn more about Covalon, please contact: Brian Pedlar, CEO, Covalon Technologies Ltd., Email: [email protected], Phone: 905.568.8400 x 233, Toll free: 1.877.711.6055; Web site: www.covalon.com; Twitter: @covalon